×

This article on Epainassist.com has been reviewed by a medical professional, as well as checked for facts, to assure the readers the best possible accuracy.

We follow a strict editorial policy and we have a zero-tolerance policy regarding any level of plagiarism. Our articles are resourced from reputable online pages. This article may contains scientific references. The numbers in the parentheses (1, 2, 3) are clickable links to peer-reviewed scientific papers.

The feedback link “Was this Article Helpful” on this page can be used to report content that is not accurate, up-to-date or questionable in any manner.

This article does not provide medical advice.

1

Treating Aspergillus Niger Osteomyelitis: Antifungal Drugs, Surgery, and Recovery

A bone infection is difficult enough to manage when bacteria are responsible. When the infection is caused by a fungus such as Aspergillus niger, treatment becomes more complicated, often requiring months of medication, careful monitoring, and sometimes surgery.

Aspergillus niger osteomyelitis is an uncommon fungal infection that develops when the organism invades bone tissue. Although this fungus is widely present in the environment, it rarely causes serious bone infections. When it does, the infection may progress gradually, causing persistent pain, inflammation, and destruction of the affected bone.

One of the challenges is that symptoms may resemble more familiar conditions. Persistent back pain, joint discomfort, or swelling may initially be attributed to arthritis, a mechanical injury, or bacterial osteomyelitis. By the time the fungal infection is identified, substantial damage may already have occurred.

Fortunately, effective treatment is possible. Antifungal medications, particularly voriconazole, form the foundation of treatment. Depending on the extent of infection, surgical removal of infected tissue and rehabilitation may also be necessary.

Understanding how Aspergillus niger osteomyelitis treatment works, why recovery takes time, and what determines the outcome can help patients and caregivers navigate this unusual condition.

Why Aspergillus Niger Osteomyelitis Requires Specialized Treatment

Unlike many bacterial bone infections, fungal osteomyelitis does not respond to conventional antibiotics. Medications commonly used for bacterial infections cannot eliminate Aspergillus niger.

The fungus can invade bone and surrounding tissues, producing inflammation and damaging the normal structure of the affected area. Infection may involve the spine, long bones, skull, ribs, or other skeletal structures.

Bone infections are also challenging because damaged and poorly vascularized areas may be difficult to treat. When portions of bone become necrotic, medication alone may not adequately control the infection.

Three factors make treatment particularly demanding:

  • Delayed diagnosis: Symptoms frequently develop gradually and may remain unexplained for weeks or months.
  • Prolonged antifungal therapy: Fungal bone infections generally require longer treatment than many uncomplicated infections.
  • Potential structural damage: Extensive infection may weaken bone, involve surrounding joints, or threaten nearby nerves.

An important distinction is that most available evidence concerns Aspergillus osteomyelitis as a group, rather than Aspergillus niger alone.

A major review of 180 patients with Aspergillus osteomyelitis found that the vertebrae were the most frequently involved bones. Pain and tenderness were common, and many patients required both antifungal treatment and surgery [1].

These findings help guide the management of Aspergillus niger bone infections, although treatment must be individualized.

How Doctors Decide on the Best Treatment for Aspergillus Niger Bone Infection

Before treatment begins, physicians need to establish that Aspergillus niger is responsible for the infection.

This is important because Aspergillus fungi are common in the environment. Finding the organism in a specimen does not automatically establish invasive infection. Doctors must interpret microbiological results alongside imaging, tissue findings, symptoms, and the patient’s medical history.

A bone biopsy or examination of tissue obtained during surgery may be necessary to confirm the diagnosis.

Once the diagnosis is established, the treatment team evaluates several questions.

How Much Bone Has Been Affected?

Magnetic resonance imaging and computed tomography can help determine the extent of infection.

Imaging may identify bone destruction, inflammation, abscess formation, involvement of nearby soft tissues, and structural instability.

When the spine is involved, imaging is especially important for identifying pressure on the spinal cord or nerve roots.

Is the Infection Localized or Spreading?

A localized infection confined to a small area of bone may be easier to manage than an infection extending into several bones, joints, or surrounding tissues.

Doctors may also investigate whether the infection originated elsewhere, particularly in the lungs, before spreading to the skeleton.

Does the Patient Have an Underlying Medical Condition?

Patients receiving immunosuppressive medications, individuals with certain immune disorders, and those who have undergone major surgery may face additional treatment challenges.

Diabetes, poor nutritional status, and other medical conditions may complicate wound healing and recovery.

The treatment plan must address these factors whenever possible.

Is Surgery Necessary?

Not every patient requires an operation.

However, surgery becomes more important when the infection has caused substantial bone destruction, an abscess, neurological compression, or instability.

The Infectious Diseases Society of America recommends surgical intervention where feasible, combined with voriconazole, for Aspergillus osteomyelitis [2].

Antifungal Medications Used to Treat Aspergillus Niger Osteomyelitis

Systemic antifungal therapy is the central component of treatment.

These medications work by interfering with fungal survival or growth, allowing the infection to be controlled over time.

The specific antifungal drug depends on the identified organism, laboratory susceptibility results when available, disease severity, other medical conditions, and potential medication interactions.

Voriconazole: The Preferred Antifungal Treatment

Voriconazole is generally the preferred antifungal medication for Aspergillus osteomyelitis.

It belongs to a class of antifungal medicines called triazoles.

Voriconazole interferes with the production of ergosterol, an important component of the fungal cell membrane. Without adequate ergosterol, the fungus cannot maintain normal membrane function.

The medication is available in oral and intravenous formulations, making it suitable for different stages of treatment.

Patients with severe infections or those unable to take oral medication may initially receive intravenous therapy. Once clinically appropriate, treatment may continue orally.

Voriconazole is recommended for Aspergillus osteomyelitis in established infectious disease guidelines [2].

The choice of oral versus intravenous treatment depends on clinical circumstances rather than a universal requirement to begin with intravenous medication.

How Effective Is Voriconazole for Fungal Bone Infections?

A systematic review published in Medical Mycology examined 186 confirmed cases of Aspergillus bone and joint infections. Among patients treated with voriconazole alone, complete infection resolution was reported in 58.6% [3].

This figure should not be interpreted as the expected success rate for every patient with Aspergillus niger osteomyelitis. The review combined different Aspergillus species, infection sites, and clinical circumstances.

Nevertheless, it demonstrates that voriconazole has an established role in treating these difficult infections.

Side Effects of Voriconazole

Because treatment may continue for months, monitoring for adverse effects is essential.

Potential side effects include:

  • Nausea and gastrointestinal discomfort.
  • Temporary visual disturbances.
  • Increased liver enzyme levels or liver injury.
  • Skin sensitivity to sunlight.
  • Changes in heart rhythm in susceptible patients.
  • Neurological symptoms, including hallucinations or confusion in some patients.

Long-term therapy may also cause additional complications, including skin changes and, rarely, painful periostitis associated with fluoride exposure.

Voriconazole interacts with several commonly prescribed medications, making medication review particularly important.

Physicians may perform blood tests to measure voriconazole concentrations and determine whether the dose needs adjustment.

Drug-level monitoring helps balance adequate antifungal exposure against the risk of toxicity [2].

Patients should never adjust or discontinue voriconazole without consulting the prescribing physician.

Amphotericin B for Severe or Difficult-to-Treat Infections

Amphotericin B is another antifungal medication that has historically been used to treat invasive Aspergillus infections.

It works by binding to components of fungal cell membranes, disrupting their integrity.

Lipid formulations, particularly liposomal amphotericin B, may be considered when voriconazole cannot be used, when intolerance develops, or when specialist evaluation indicates that another treatment is necessary.

However, amphotericin B has important limitations.

Potential adverse effects include kidney injury, electrolyte disturbances, and infusion-related reactions.

For this reason, patients receiving amphotericin B generally require monitoring of kidney function, potassium, magnesium, and other relevant laboratory results.

Although amphotericin B remains a treatment option, voriconazole is generally preferred for Aspergillus osteomyelitis under established guidelines [2].

Posaconazole and Isavuconazole as Alternative Antifungal Drugs

Other triazole antifungal agents may be considered in selected patients.

Posaconazole has activity against various Aspergillus species and may be useful when a patient cannot tolerate the preferred medication or requires an alternative treatment strategy.

Isavuconazole is another antifungal agent used in invasive aspergillosis. It may be considered under specialist supervision when voriconazole is unsuitable.

However, the evidence supporting these medications specifically for Aspergillus bone infections remains limited compared with the experience available for voriconazole.

A published case involving vertebral osteomyelitis caused by Aspergillus flavus described successful treatment with surgery and posaconazole after the patient developed intolerance and hepatitis associated with voriconazole [4].

This illustrates the potential role of alternative medications, although a single case involving another Aspergillus species cannot establish equivalent effectiveness for Aspergillus niger osteomyelitis.

Can Multiple Antifungal Medications Be Used Together?

In difficult cases, physicians may consider combination or sequential antifungal treatment.

However, using multiple antifungal drugs is not automatically more effective.

The 2022 systematic review found no statistically significant difference in complete infection resolution between antifungal monotherapy and combination or sequential regimens across the cases examined [3].

Combination treatment may still be considered in unusual or severe situations, but it is not routinely necessary for every patient.

The decision should be made by an infectious disease specialist familiar with invasive fungal infections.

How Long Does Antifungal Treatment for Aspergillus Niger Osteomyelitis Last?

One of the most common questions patients ask is how long they will need antifungal medication.

Unfortunately, fungal bone infections rarely have a short or predictable treatment course.

The Infectious Diseases Society of America recommends treating Aspergillus osteomyelitis for at least eight weeks, with courses extending beyond six months frequently necessary [2].

The actual duration depends on the severity of infection, response to treatment, immune function, and whether infected tissue has been surgically removed.

Why Treatment May Continue for Several Months

Bone tissue heals slowly, particularly after infection has caused extensive destruction.

Antifungal therapy must continue long enough to adequately control the infection and reduce the likelihood of recurrence.

Several circumstances may lead to a longer treatment course:

  • Extensive bone destruction.
  • Vertebral infection involving multiple spinal levels.
  • Residual infected tissue following surgery.
  • Persistent abscesses or surrounding soft-tissue involvement.
  • Significant immunosuppression.
  • Slow clinical improvement or evidence of persistent infection.

In the review of 180 Aspergillus osteomyelitis cases, the median antifungal treatment duration was 90 days, but reported courses varied considerably [1].

This variation reflects the complexity of treating fungal bone infections.

Can Treatment Stop When the Pain Improves?

Improvement in pain does not necessarily mean the infection has been eradicated.

Symptoms may decrease before the affected bone and surrounding tissues have adequately recovered.

Stopping antifungal medication prematurely may increase the risk of persistent or recurrent infection.

Physicians consider the overall clinical response, laboratory findings, imaging when indicated, and other risk factors before deciding that treatment can safely end.

When Is Surgery Needed for Aspergillus Niger Osteomyelitis?

Although antifungal medication is essential, some patients require surgery to achieve infection control.

Surgery may be particularly valuable when infected tissue cannot be adequately managed with medication alone.

A review of 186 Aspergillus bone and joint infection cases found that complete infection resolution was reported in 70.0% of patients treated with surgery plus antifungal therapy, compared with 40.5% receiving antifungal treatment without surgery [3].

These observational findings do not prove that every patient benefits from surgery. Patients differ in disease severity, infection location, and suitability for an operation.

However, they support the importance of surgical assessment in appropriately selected cases.

Surgical Debridement to Remove Infected Bone

Surgical debridement involves removing infected, damaged, or dead tissue.

The procedure is intended to reduce the burden of infection and create more favorable conditions for healing.

Depending on the location, the surgeon may remove necrotic bone, drain infected collections, and clean affected surrounding tissues.

When the infection involves a limb, debridement may help preserve function and prevent additional damage.

The extent of surgery depends on how much tissue has been affected.

Drainage of Abscesses

Fungal osteomyelitis may occasionally produce collections of infected material within or around affected bone.

These abscesses can contribute to persistent inflammation and tissue damage.

When an abscess is large, inaccessible to adequate medical control, or threatening surrounding structures, surgical or image-guided drainage may be necessary.

The collected material may also provide useful samples for fungal culture and additional testing.

Spinal Surgery for Aspergillus Niger Vertebral Osteomyelitis

Spinal osteomyelitis deserves particular attention because the vertebrae surround the spinal cord and nerve roots.

Advanced infection may damage vertebral bodies, produce spinal deformity, or cause pressure on neurological structures.

Surgery may be recommended when patients develop:

  • Progressive neurological weakness.
  • Spinal cord or nerve root compression.
  • Significant spinal instability.
  • Progressive deformity.
  • Abscesses requiring drainage.
  • Worsening symptoms despite appropriate antifungal treatment.

Possible procedures include surgical decompression, removal of infected tissue, and spinal stabilization or fusion.

Spinal fusion may be required when infection has weakened the structural integrity of the spine.

The purpose is not simply to remove fungal infection, but also to protect neurological function and provide mechanical stability.

Can Aspergillus Osteomyelitis Be Treated Without Surgery?

Yes. Some patients can recover with antifungal medication alone.

This may be possible when the infection is localized, the affected bone remains stable, there is no significant neurological compression, and the patient responds appropriately to medication.

The 2016 infectious disease guidelines acknowledge that antifungal treatment alone may be sufficient in selected patients without substantial instability, neural compression, or disease progression [2].

However, close follow-up is necessary.

If symptoms worsen or complications develop, the treatment strategy may need to change.

Recovery After Aspergillus Niger Osteomyelitis Treatment

Recovering from fungal osteomyelitis involves more than eliminating the organism.

Even after the infection has been controlled, patients may experience pain, weakness, stiffness, or difficulty returning to their usual activities.

The duration of recovery varies substantially.

Patients with a small, localized infection may recover more quickly than those with extensive bone destruction or spinal involvement.

Early Recovery: Controlling the Infection

The initial phase focuses on controlling fungal growth, reducing inflammation, and identifying complications.

Patients may begin to notice gradual improvement in pain and general well-being.

However, improvement is not always immediate.

Persistent discomfort during the early treatment period does not necessarily mean that antifungal therapy is failing.

Doctors monitor the overall pattern of symptoms, physical findings, and laboratory results.

Patients with severe infections may require hospitalization, particularly when intravenous treatment, surgery, or neurological monitoring is necessary.

Bone Healing and Functional Recovery

Once infection control is established, attention increasingly turns toward restoring mobility and function.

Bone healing may continue long after systemic symptoms improve.

The recovery process may involve:

  • Gradually increasing physical activity.
  • Protecting weakened or surgically treated bones.
  • Improving joint mobility.
  • Restoring muscle strength.
  • Managing residual pain.
  • Returning to work and everyday activities.

Recovery is especially individualized following spinal surgery or extensive debridement.

Some patients may require assistive devices, temporary activity restrictions, or additional orthopedic follow-up.

Physical Therapy After Aspergillus Osteomyelitis

Physical therapy may be recommended once the treating physician determines that movement and strengthening activities are safe.

Rehabilitation can help address muscle weakness and reduced mobility resulting from prolonged pain, inactivity, hospitalization, or surgery.

A physical therapist may develop exercises to improve flexibility, strength, balance, and functional endurance.

However, aggressive exercise should be avoided when the affected bone remains unstable or when postoperative restrictions are in place.

Patients recovering from vertebral osteomyelitis may require special precautions regarding bending, lifting, and twisting.

The rehabilitation program should reflect the patient’s bone stability, neurological status, and surgical history.

Managing Pain During Recovery From Fungal Osteomyelitis

Pain management is an important part of recovery, but it must not interfere with treatment of the underlying infection.

Depending on the circumstances, physicians may recommend appropriate pain medication, activity modification, and rehabilitation.

Some patients experience lingering discomfort even after successful treatment because of structural damage, inflammation, or reduced muscle conditioning.

Others may develop neuropathic pain when infection or inflammation has affected nearby nerves.

Pain management should be individualized, especially in patients taking long-term antifungal medication.

Certain medicines can interact with voriconazole or other antifungal drugs, making a complete medication review important.

Persistent pain should also be assessed carefully to distinguish expected recovery-related discomfort from possible infection progression.

How Doctors Monitor Whether Aspergillus Niger Osteomyelitis Treatment Is Working

Regular follow-up is essential throughout treatment.

Doctors must determine whether the infection is responding, whether medication remains safe, and whether additional intervention is required.

Monitoring Pain, Swelling, and Mobility

Clinical improvement is one of the most useful indicators of treatment response.

Doctors assess whether pain is decreasing, mobility is improving, and the patient is regaining function.

They also look for new swelling, drainage, tenderness, fever, or neurological symptoms.

A worsening clinical picture may prompt additional investigations.

Blood Tests During Antifungal Treatment

Blood testing may serve several purposes.

Inflammatory markers, including C-reactive protein and erythrocyte sedimentation rate, can help monitor changes in inflammation.

Liver function testing is particularly important during prolonged treatment with certain antifungal medications.

Patients receiving amphotericin B may require additional kidney function and electrolyte monitoring.

Voriconazole blood concentrations may also be measured to help optimize treatment.

Repeat MRI

Magnetic resonance imaging can be particularly useful when physicians suspect persistent infection, abscess formation, or neurological complications.

However, imaging findings may remain abnormal even after successful treatment.

Guidelines for vertebral osteomyelitis caution against routine follow-up magnetic resonance imaging in patients showing a favorable clinical and laboratory response [5].

These recommendations largely concern vertebral osteomyelitis in general rather than fungal infection specifically, so imaging decisions should be individualized.

Repeat imaging is more useful when symptoms worsen, new neurological problems develop, or treatment failure is suspected.

Can Aspergillus Niger Osteomyelitis Return After Treatment?

Recurrence is a significant concern with fungal bone infections.

A patient may initially respond to treatment but experience renewed symptoms after antifungal medication is discontinued.

This may occur when residual infection persists, infected tissue has not been fully removed, or an underlying immune-related risk remains.

In the 2014 review of Aspergillus osteomyelitis, relapse occurred in 8% of patients treated with surgery and antifungal medication, compared with 30% of those treated with antifungal medication alone [1].

These figures describe historical cases involving multiple Aspergillus species and should not be used to predict an individual patient’s risk.

Nevertheless, they highlight why carefully selected surgical intervention and adequate treatment duration can matter.

Warning Signs That Require Medical Reassessment

Patients should contact their treating physician if they experience:

  • Increasing pain after an initial period of improvement.
  • New swelling, redness, or drainage.
  • Recurring fever or unexplained illness.
  • Increasing difficulty walking or moving the affected area.
  • New numbness, weakness, or neurological symptoms.

New or progressive weakness, loss of bladder or bowel control, or severe neurological symptoms in someone with spinal infection require emergency medical evaluation.

Early recognition of complications can help prevent permanent damage.

What Determines the Prognosis of Aspergillus Niger Osteomyelitis?

The outlook depends on several factors rather than on the fungal species alone.

Early Diagnosis and Appropriate Antifungal Therapy

Early diagnosis allows treatment to begin before extensive tissue destruction develops.

Confirming the organism through appropriate testing helps physicians select effective antifungal medication.

Extent and Location of the Bone Infection

A small, localized infection may have a more favorable prognosis than extensive disease affecting several bones.

Spinal infections may carry additional risks because of their proximity to the spinal cord and nerve roots.

Immune System Function

Patients with significant immunosuppression may require closer monitoring and longer treatment.

When clinically feasible, physicians may adjust immunosuppressive treatment to improve infection control.

These decisions require careful coordination because reducing immunosuppression may not be safe for every patient.

Need for Surgical Intervention

When infected tissue, instability, or abscess formation makes surgery necessary, timely intervention may improve the chances of controlling the infection and preserving function.

However, surgery carries its own risks and may not be suitable for every patient.

Adherence to Long-Term Treatment

Taking antifungal medication consistently is essential.

Missed doses, treatment interruptions, and unmanaged medication interactions may compromise therapy.

Regular follow-up also allows adverse effects to be identified before they become serious.

What Research Tells Us About Aspergillus Niger Osteomyelitis Treatment

Because Aspergillus niger osteomyelitis is exceptionally rare, much of the clinical understanding comes from studies involving several Aspergillus species.

A 2024 case report published in BMJ Case Reports described a man in his seventies who developed knee joint infection caused by Aspergillus niger after arthroscopy.

Persistent pain and swelling led to further investigation, and tissue samples ultimately identified the fungus. The patient underwent surgical debridement and received voriconazole, with significant clinical improvement and eradication of infection [6].

Although this case involved septic arthritis rather than confirmed osteomyelitis, it provides species-specific evidence relevant to the management of invasive musculoskeletal Aspergillus niger infection.

Additional evidence comes from a 2024 observational study of fungal osteomyelitis affecting the jaw in patients recovering from coronavirus disease. Aspergillus niger was among the organisms identified, and patients with Aspergillus infection were treated with oral voriconazole and surgical debridement [7].

These reports support the role of antifungal treatment and appropriate surgery. However, they do not establish a treatment protocol specifically validated for Aspergillus niger osteomyelitis.

Larger studies are still needed to determine the best duration of therapy, identify factors predicting recurrence, and compare alternative antifungal medications.

Frequently Asked Questions About Aspergillus Niger Osteomyelitis Treatment

Is Aspergillus Niger Osteomyelitis Curable?

Yes. Aspergillus niger osteomyelitis can be successfully treated, particularly when the infection is diagnosed accurately and appropriate antifungal treatment is started.

Some patients also require surgical removal of infected tissue.

The possibility of complete recovery depends on the extent of infection, underlying health conditions, and response to treatment.

What Is the Best Antifungal Medicine for Aspergillus Niger Osteomyelitis?

Voriconazole is generally the preferred antifungal medication based on established guidance for Aspergillus osteomyelitis.

Alternative medications may be considered when voriconazole is unsuitable or ineffective.

The final choice should account for fungal susceptibility, drug interactions, and the patient’s medical condition.

How Many Months Does Aspergillus Niger Osteomyelitis Treatment Take?

Treatment generally requires at least eight weeks, and courses longer than six months are frequently necessary.

Some patients require even longer therapy.

Treatment duration should be determined by an infectious disease specialist based on the clinical response and extent of infection.

Can Aspergillus Niger Osteomyelitis Be Treated With Antibiotics?

No. Conventional antibacterial antibiotics do not treat Aspergillus fungal infections.

Antifungal medications are required.

If a patient also has a bacterial infection, separate antibacterial therapy may be necessary.

Is Surgery Always Required for Fungal Bone Infection?

No. Selected patients with localized disease, stable bone structures, and a favorable response to antifungal medication may be treated without surgery.

Surgery is more likely to be needed when there is extensive tissue damage, an abscess, spinal instability, neurological compression, or inadequate response to medical treatment.

Can Patients Walk Normally After Spinal Aspergillus Osteomyelitis?

Some patients regain normal or near-normal mobility following successful treatment.

However, recovery depends on the severity of infection, structural spinal damage, neurological involvement, and whether surgery was necessary.

Physical rehabilitation may help restore strength and mobility.

Can Aspergillus Niger Osteomyelitis Cause Permanent Bone Damage?

Yes. Severe infections can destroy bone tissue and alter normal skeletal structure.

Even after the fungus has been controlled, residual pain, stiffness, deformity, or neurological problems may persist.

Early treatment can help reduce the risk of these complications.

Conclusion

Treating Aspergillus niger osteomyelitis requires patience, careful medical management, and often a multidisciplinary approach.

Voriconazole remains the preferred antifungal treatment for Aspergillus bone infections, although other medications may be necessary in selected circumstances. Surgical debridement, drainage, or stabilization may also play an important role when infection causes extensive tissue destruction or threatens surrounding structures.

Recovery can take several months, particularly when the spine is involved or the patient requires major surgery. Regular monitoring, appropriate rehabilitation, and completing the prescribed antifungal treatment are essential parts of care.

While Aspergillus niger osteomyelitis is rare, successful treatment is possible. Early recognition, accurate diagnosis, and individualized treatment offer the best opportunity to control infection, preserve bone function, and reduce the risk of recurrence.

References:

  1. 1. Gamaletsou MN, Rammaert B, Bueno MA, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. Journal of Infection. 2014;68(5):478-493. https://doi.org/10.1016/j.jinf.2013.12.008
  2. 2. Patterson TF, Thompson GR III, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016;63(4):e1-e60. https://doi.org/10.1093/cid/ciw326
  3. 3. Tsantes AG, Papadopoulos DV, Markou E, et al. Aspergillus spp. osteoarticular infections: an updated systematic review on the diagnosis, treatment and outcomes of 186 confirmed cases. Medical Mycology. 2022;60(8):myac052. https://doi.org/10.1093/mmy/myac052
  4. 4. Kim MGJ, Overton K. Successful treatment of vertebral osteomyelitis due to Aspergillus flavus in an immunocompetent patient. BMJ Case Reports. 2022;15(11):e251101. https://doi.org/10.1136/bcr-2022-251101
  5. 5. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clinical Infectious Diseases. 2015;61(6):e26-e46. https://doi.org/10.1093/cid/civ482
  6. 6. Agathangelidis F, Nikopoulou A, Vyzantiadis TA, et al. Aspergillus niger as a rare cause of postarthroscopy knee septic arthritis in a healthy patient. BMJ Case Reports. 2024;17(9):e259936. https://casereports.bmj.com/content/17/9/e259936
  7. 7. Datarkar A, Gadve V, Dhoble A, et al. Osteomyelitis of Jaw Bone due to Aspergillosis in Post-COVID-19 Patients: An Observational Study. Journal of Maxillofacial and Oral Surgery. 2024;23(2):308-315. https://pubmed.ncbi.nlm.nih.gov/38601236/
Team PainAssist
Team PainAssist
Written, Edited or Reviewed By: Team PainAssist, Pain Assist Inc. This article does not provide medical advice. See disclaimer
Last Modified On:November 17, 2026

Recent Posts

Related Posts